Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression.

Zydus Lifesciences on Wednesday said it has launched ANVIMO, a breakthrough medication for the prevention of Cytomegalovirus ...

Zydus Lifesciences introduces ANVIMO, a cost-effective medication for preventing CMV infection in transplant patients, ...

Zydus Lifesciences introduces ANVIMO (Letermovir) for CMV prevention in transplant patients, offering a safer, ...

Zydus Lifesciences launches ANVIMO, a breakthrough drug for preventing Cytomegalovirus infection in transplant patients, ...

Zydus Lifesciences announced that it has launch ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) ...

The Indian stock market is expected to open on a cautious note on Wednesday, with Nifty Futures starting lower, signaling a ...

While cytomegalovirus remains the most common cause of congenital infection in the United States, the possibility of effective treatment with Ganciclovir (Hoffman-LaRoche, Basel, Switzerland ...

Current options include: Cytogam (cytomegalovirus immune globulin intravenous), a drug that can be given to pregnant people to limit congenital CMV impacts. Cytovene (ganciclovir), to treat a newborn ...